The use of hydroxyurea in the real life of MIOT network: an observational study.
Paolo RicchiAntonella MeloniPaolo RiganoLaura PistoiaAnna SpasianoMassimo AllòGiuseppe MessinaAntonella QuartaRosamaria RossoAlessandra QuotaAldo FilosaAurelio MaggioAlessia PepePublished in: Expert opinion on drug safety (2022)
Our findings seemed to suggest that in several NTDT patients HU could be still a valid option to limit the advance in overall disease clinical burden without carrying significant adverse events and increase in mortality.